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Abstract: A number of genome-wide association studies (GWASs) and meta-analyses of genetic
variants have been performed in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
We reinterpreted previous studies using false-positive report probability (FPRP) and Bayesian false
discovery probability (BFDP). This study searched publications in PubMed and Excerpta Medica
Database (EMBASE) up to February 2018. Identification of noteworthy associations were analyzed
using FPRP and BFDP, and data (i.e., odds ratio (OR), 95% confidence interval (CI), p-value) related to
significant associations were separately extracted. Using filtered gene variants, gene ontology (GO)
enrichment analysis and protein–protein interaction (PPI) networks were performed. Overall,
241 articles were identified, and 7 were selected for analysis. Single nucleotide polymorphisms (SNPs)
discovered by GWASs were shown to be noteworthy, whereas only 27% of significant results from
meta-analyses of observational studies were noteworthy. Eighty-five percent of SNPs with borderline
p-values (5.0 × 10−8 < p < 0.05) in GWASs were found to be noteworthy. No overlapping SNPs
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were found between PR3-ANCA and MPO-ANCA vasculitis. GO analysis revealed immune-related
GO terms, including “antigen processing and presentation of peptide or polysaccharide antigen via
major histocompatibility complex (MHC) class II”, “interferon-gamma-mediated (IFN-γ) signaling
pathway”. By using FPRP and BFDP, network analysis of noteworthy genetic variants discovered
genetic risk factors associated with the IFN-γ pathway as novel mechanisms potentially implicated
in the complex pathogenesis of ANCA-associated vasculitis.
Keywords: antineutrophil cytoplasmic antibody (ANCA); proteinase 3; myeloperoxidase; single
nucleotide polymorphism; vasculitis; meta-analysis; genome-wide association study
1. Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune
diseases characterized by the inflammation of small vessels. Clinical overlap among the different
subtypes of AAV, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and
eosinophilic granulomatosis with polyangiitis (EGPA) can result in diagnostic difficulties [1].
The clinical manifestations of the disease types can vary widely; most patients have signs of a lung,
kidney, and/or ear, nose, and throat (ENT) involvement. ENT involvement is especially common
in patients with GPA and EGPA [1]. A positive test for ANCA aids in the initial diagnosis of AAV.
However, overlaps between disease phenotype and ANCA serotype limit the ability of the ANCA
serotype to discriminate between the different disease phenotypes [2]. In general, a perinuclear ANCA
(p-ANCA)—target antigen MPO—is found in 60–80% of MPA patients. On the other hand, cytoplasmic
ANCA (c-ANCA)—target antigen proteinase 3 (PR3)—is frequently found in patients with severe GPA
(approximately 90% of patients) and to a lesser degree in those with non-severe disease (approximately
50% of patients) [1].
Even though the exact pathogenesis of AAV is unclear, it is generally believed that AAV has
a genetic background. Several genome-wide association studies (GWASs) and meta-analyses of
observational studies employing single nucleotide polymorphisms (SNPs) revealed a number of genetic
variants to be associated with AAV [3–6]. Up to date, there have been three GWASs and meta-analyses
with replication cohorts: two by the US Vasculitis Clinical Research Consortium (VCRC) [4,6]
and one by the European Vasculitis Genetic Consortium (EVGC) [3]. Moreover, Rahmattulla and
co-workers performed a meta-analysis with inclusion of EVGC GWAS data and other meta-analyses
of observational studies [5].
Because the prior probabilities of genetic associations are low, the number of false-positive
associations that are generated by chance alone is high. Not accounting for these low probabilities in the
statistical analysis leads to an increased likelihood of finding false-positive associations. Since concerns
have been raised about true positives of the discovered genetic variants in AAV, the aim of this study
was to investigate whether these genetic variants are false-positives or are truly associated with AAV
by applying a Bayesian approach. Moreover, we discussed and re-analyzed the filtered data based on
the integration of the available results for genetic variants.
2. Experimental Section
2.1. Method
Database Search and Selection
The eligible studies were selected according to the standardized reporting protocol of
systematic reviews and meta-analyses PRISMA (Preferred Reporting Items for Systematic reviews
and Meta-Analyses) checklist (Table S1) [7]. A systematic search was performed in PubMed and
EMBASE to retrieve studies published before 20 February 2018. Antineutrophil cytoplasmic antibody
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(ANCA)-associated vasculitis, polymorphisms, meta, genetic, variant and genome-wide association
study (GWAS) were the terms used in the systematic search. At the end of the systematic search,
241 articles were identified, 13 were screened in detail, and 7 were selected for analysis [4–6,8–11].
(Figure 1 and Table S2).J. Clin. Med. 2019, 8, x FOR PEER REVIEW  1 of 21 
 
 
Figure 1. The process of the systematic search performed to study genetic variants in 
ANCA-associated vasculitis. Abbreviations used: AAV (ANCA-associated vasculitis), 
ANCA (anti-neutrophil cytoplasmic antibody), and GWAS (genome-wide association 
study). 
i re 1. The process of the systematic search performed to study genetic variants in ANCA-associated
vasculitis. Abbreviations used: AAV (ANCA-associated vasculitis), ANCA (anti-neutrophil cytoplasmic
antibody), and GWAS (genome-wide association study).
The inclusion criteria were (1) a genetic meta-analysis or GWAS providing information of odds
ratios (OR), 95% confidence intervals (CI) in AAV (2) studies written in English, and (3) most recent
larger meta-analyses (if smaller numbers have been analyzed before). The exclusion criteria were (1)
studies not related to genetic polymorphisms or AAV, (2) articles not providing accurate data sets
(i.e., review articles), and (3) older meta-analyses with overlapping genetic variants.
Data elements collected from meta-analyses included, when available, author, publication year,
gene variant, single nucleotide polymorphism ID (rsID), genotype comparison, OR, 95% CI, minor
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allelic frequency, ethnicity of study population, number of cases and controls, publication bias, and
heterogeneity. Results of various subgroup analyses (i.e., Caucasian vs. mixed-population) were
also extracted.
2.2. Statistical Method
Data related to statistically significant associations (i.e., OR, 95% CI, p-value) and heterogeneity
parameters (i.e., p-value and I2) were separately extracted. Statistically significant associations were
selected if the reported p-value was <5 × 10−8 for results of meta-analyses in GWASs for both
the discovery and replication cohorts, and <0.05 for meta-analysis of general observational studies
(i.e., case-control studies).
To assess and identify noteworthy associations, false-positive report probability (FPRP) and
Bayesian false discovery probability (BFDP) were applied [12,13]. FPRP is defined as “the probability
of no true association between a gene variant and disease (null hypothesis)” for a statistically significant
association [12], and detailed calculation is presented in the supplementary file (Equation S1). FPRP
is calculated with the observed p-value for the association, the statistical power of the test, and the
prior probability that a molecular association is real. In this review, we calculated FPRP at two levels
of assumed prior probabilities, which were 10−3 and 10−6. The interpretation for the noteworthiness
of significant associations using FPRP is that the FPRP value of <0.2 is noteworthy [12].
BFDP is another Bayesian statistical method for detecting the true association between a gene
variant and disease [13]. Main differences of BFDP compared to FPRP is that BFDP is independent
from a statistical power and its approximation is based on a logistic regression model instead of a
standard normal distribution [13]. The interpretation for the noteworthiness of significant associations
using BFDP is that the BFDP value of <0.8 is noteworthy [13].
2.3. Outcomes
This study presents both FPRP and BFDP methods because the genetic epidemiologists and clinicians
use BFDP less frequently than FPRP [12], although BFDP is a more recently developed method with
a more substantial justification for its use [13]. By summarizing both results of FPRP and BFDP,
we provide the readers options for interpreting noteworthiness.
2.4. Construction of PPI (Protein–Protein Interaction) Network
The STRING 9.1 network database is one of the largest databases of direct (physical) protein–protein
interactions and indirect (functional) interactions constructed from various data sources including
genomic context predictions, high-throughput experiments, co-expression, and known databases [14].
The STRING database covers 9.6 million proteins from more than 2031 organisms. In our study, we
used STRING database to identify the PPIs associated with genes mapping to AAV, GPA, PR3-ANCA,
and MPO-ANCA SNPs.
3. Results
3.1. Computation of Noteworthy Variants
The re-analysis of genetic variants was mainly driven by two categories of studies: one meta-analysis
of observational studies and two GWASs with replication cohorts (combined analysis). All statistically
significant SNPs and variants (p < 0.05 for observational studies and p < 5.0 × 10−8 for GWASs)
reported in the meta-analyses were included in this study. In addition, variants found in the GWAS
meta-analysis with 5.0 × 10−8 < p < 0.05, which were rejected as insignificant in their interpretation,
were re-analyzed. Whether a variant was noteworthy was determined based on satisfaction of the
condition in at least one of the values (FPRP < 0.2 and BFDP < 0.8). The reported results were based on
the various subtypes (GPA and MPA). In this study we followed the classification system used in the
original studies.
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First, only 42/158 (27%) genetic comparisons in the meta-analysis of observational studies
were noteworthy after re-analysis. In AAV, FPRP estimation resulted in 8/42 (19%) and 3/42 (7%)
noteworthy genetic comparisons at the prior probability of 10−3 and 10−6 with the statistical power to
detect an OR of 1.2. Likewise, 16/42 (38%) and 12/42 (26%) of comparisons were noteworthy at the
prior probability of 10−3 and 10−6 with the statistical power to detect an OR of 1.5. BFDP estimation
demonstrated 10/42 (24%) and 6/42 (14%) comparisons noteworthy at the prior probability of 10−3
and 10−6, respectively (Table 1 and Table S3).
In GPA, 4/50 (8%) and 1/50 (2%) comparisons were noteworthy in FPRP with the statistical power
to detect an OR of 1.2 at the prior probability of 10−3 and 10−6; 9/50 (18%), 3/50 (6%) of comparisons
with the statistical power to detect an OR of 1.5 at the prior probability of 10-3 and 10-6, respectively.
In comparison, 15/50 (30%) and 9/50 (18%) variations were noteworthy in BFDP estimation at the
prior probability of 10−3 and 10−6 (Table 1 and Table S3).
In PR3-ANCA, 5/24 (21%) comparisons were noteworthy in FPRP while 10/24 (42%) were found
noteworthy in BFDP. Variants marked with ‘NA’ in the tables were not assessable with FPRP due to
the mathematical error of calculating the inverse of the cumulative distribution, but BFDP was still
computable. All the noteworthy variants in PR3-ANCA with FPRP estimation were also noteworthy
in BFDP estimation (Table 2 and Table S4). No noteworthy comparison was observed in both MPA and
MPO-ANCA vasculitis (Tables 1 and 2 and Tables S3 and S4).
Secondly, 22/28 (79%) SNPs in the meta-analyses of GWASs were noteworthy in total. Without
exception, statistically significant SNPs discovered by GWAS meta-analyses (p < 5.0 × 10−8) were also
noteworthy in FPRP estimation at the prior probabilities of either 10-3 or 10-6 with the statistical power
to detect an OR of 1.2 or 1.5 and in BFDP estimation at the probability of 10−3 or 10−6 except where
mathematical errors did not allow FPRP. However, among the 14 SNPs with p-values ranging between
0.05 and 5.0 × 10−8, which were considered as statistically non-significant in GWAS meta-analyses,
8 SNPs were reported noteworthy in both FPRP and BFDP estimation (Table 4 and Table S5).
We could re-analyze one GWAS of patients with GPA, while the remaining two GWASs were
unable to be re-assessed due to the absence of 95% CI data. With our re-analyses, all the significant
SNPs (p < 5.0 × 108) observed in the GWASs were noteworthy in FPRP and BFDP estimation. However,
among the borderline SNPs rejected by the GWAS with p > 5.0 × 10−8, 53/62 (85%) of the SNPs were
found noteworthy in our re-analysis (Table 4 and Table S6).
3.2. Gene Network Analysis
FPRP and BFDP computation reported all the SNPs with genome-wide significance discovered
by GWASs as noteworthy, which may indicate that SNPs identified to be significant within GWASs are
highly credible due to a conservative statistical standard and larger sample size. Based on this result,
the SNPs’ related protein–protein interaction (PPI) network of AAV subgroups and a Venn diagram
of SNPs were constructed with the noteworthy genetic variants sorted by FPRP and BFDP and all
the meaningful GWAS SNPs. The Venn diagram showed that no SNPs overlap between PR3-ANCA
and MPO-ANCA vasculitis (Figure 2A and Figure S1). The PPI networks among genes mapping to
PR3-ANCA and MPO-ANCA vasculitis-associated SNPs showed closer connections (Figure 2B,C).
Interestingly, the genes associated with interferon-gamma (IFN-γ)-mediated signaling pathway are
highly enriched in both PR3-ANCA and MPO-ANCA vasculitis-associated SNPs (e.g., yellow nodes in
the PPI networks). In addition, the MPA subtype was not included in the diagram, as no noteworthy
SNPs have been reported in our analysis. The PPI network of AAV showed a variety of network
connections. The major genes included in the network were major histocompatibility complex (MHC)
class I and II genes (i.e., human leukocyte antigen (HLA)-A, -B, -C, -G, -F, -DPA1, -DPB1, -DQB1,
-DRA). Other subtypes are shown in Figure 3 and Figure S2.
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Table 1. Meta-analysis results of observational studies; gene variants with statistical significance (p-value < 0.05), found to be noteworthy by false-positive report
probability (FPRP) or Bayesian false discovery probability (BFDP) for each clinical diagnosis antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV),
granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA)).
Gene/
Variant
Minor
Allele/
Comparison
OR (95% CI)
p-Value for
Meta-Analysis
Publications
(n)
Diagnosis
(Clinical
Subtypes)
No. of
Cases/
Controls
I2 (%) I2 (P)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001
Author, YearOR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
CD226
rs763361 T
1.14
(1.07–1.21) <0.001 3 AAV 2422/17898 0 0.444 0.792 0.954 1.000 0.017 0.945 0.016 0.942 0.437 0.999
Rahmattulla, et al.
2016 [5]
CTLA-4
rs3087243
(CT60)
A 0.81(0.75–0.87) <0.001 3 AAV 2015/7855 25 0.262 0.122 0.218 1.000 0.000 0.033 0.000 0.007 0.001 0.347
Rahmattulla, et al.
2016 [5]
CTLA-4 (AT)86
0.54
(0.43–0.67) <0.001 4 AAV 303/543 89 <0.001 0.946 0.000 0.028 0.348 0.998 0.001 0.437 0.010 0.913
Rahmattulla, et al.
2016 [5]
CTLA-4
rs3087243
(CT60)
AA vs. GG 0.693(0.512–0.796) 6.39 × 10
−5 2 AAV 797/9669 57.7 0.124 0.005 0.708 0.045 0.824 0.000 0.029 0.018 0.948 Lee, et al. 2012 [8]
HLA-DPA1
rs9277341 C
0.35
(0.30–0.40) <0.001 2 AAV 1032/2200 54 0.116 0.215 NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
HLA-DPB2
rs3130215 A
1.40
(1.29–1.52) <0.001 3 AAV 1417/7249 99 <0.001 0.446 0.000 0.950 0.000 0.000 0.000 0.000 0.000 0.000
Rahmattulla, et al.
2016 [5]
HLA-DRB4 - 1.69(1.36–2.10) <0.001 4 AAV 260/1845 61 0.055 0.533 0.001 0.141 0.686 1.000 0.015 0.940 0.259 0.997
Rahmattulla, et al.
2016 [5]
HSD17B8
rs421446 C
0.40
(0.34–0.48) <0.001 2 AAV 738/1872 0 0.620 NA NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
IRF5
rs10954213 G
0.77
(0.70–0.83) <0.001 3 AAV 1535/6977 99 <0.001 0.948 0.019 1.000 0.000 0.000 0.000 0.000 0.000 0.001
Rahmattulla, et al.
2016 [5]
PTPN22
rs2476601 T vs. C
1.415
(1.228–1.630) 1.59 × 10
−6 3 AAV 1184/10459 0 0.393 0.481 0.011 0.791 0.119 0.931 0.002 0.160 0.091 0.990 Lee, et al. 2012 [8]
PTPN22
rs2476601 A
1.39
(1.24–1.56) <0.001 4 AAV 2099/8678 0 0.693 0.500 0.006 0.902 0.004 0.780 0.000 0.024 0.002 0.654
Rahmattulla, et al.
2016 [5]
RING1/RXRB
rs213213 A
1.71
(1.57–1.86) <0.001 3 AAV 1414/7238 73 0.026 0.187 NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
RXRB
rs6531 C
1.63
(1.50–1.77) <0.001 3 AAV 1557/6955 96 <0.001 0.292 NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
RXRB
rs9277935 T
0.44
(0.37–0.50) <0.001 3 AAV 1417/7233 73 0.025 0.393 NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
SERPINA 1 Z allele 2.94(2.22–3.88) <0.001 8 AAV 3662/8581 41 0.092 0.078 0.000 0.000 0.173 0.995 0.000 0.025 0.000 0.005
Rahmattulla, et al.
2016 [5]
TLR9
rs352162 T
1.58
(1.43–1.75) <0.001 1 AAV 1289/1898 96 <0.001 NA NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
PTPN22
rs2476601 T vs. C
2.042
(1.534–2.719) 1.02 × 10
−6 2 ANCA (+)GPA - 0 0.989 NA 0.000 0.017 0.882 0.999 0.056 0.855 0.375 0.998 Lee, et al. 2012 [8]
CD226
rs763361 T
1.19
(1.11–1.28) <0.001 3 GPA 2021/17898 72.2 0.006 0.589 1.000 0.005 0.832 0.003 0.745 0.124 0.993
Rahmattulla, et al.
2016 [5]
CLTA-4
rs3087243 A
0.80
(0.73–0.87) <0.001 3 GPA 1561/7855 38.7 0.180 0.170 1.000 0.001 0.521 0.000 0.156 0.011 0.915
Rahmattulla, et al.
2016 [5]
CTLA-4 (AT)86
0.44
(0.34–0.57) <0.001 3 GPA 210/432 86.5 0.001 0.000 0.001 0.434 0.999 0.001 0.381 0.002 0.670
Rahmattulla, et al.
2016 [5]
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Table 1. Cont.
Gene/
Variant
Minor
Allele/
Comparison
OR (95% CI)
p-Value for
Meta-Analysis
Publications
(n)
Diagnosis
(Clinical
Subtypes)
No. of
Cases/
Controls
I2 (%) I2 (P)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001
Author, YearOR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
CTLA-4
rs3087243
(CT60)
A vs. G 0.79(0.70–0.89) 9.83 × 10
−5 2 GPA 880/1969 0.190 0.997 0.358 0.982 0.096 0.914 0.779 1.000 Chung, et al. 2012[10]
HLA-DPA1
rs9277341 C
0.35
(0.30–0.41) <0.001 2 GPA 1032/2200 54.8 0.109 NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
HLA-DPB1*0301 - 0.23(0.16–0.32) <0.001 3 GPA 774/918 61.7 0.050 NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
HLA-DPB1*0401 - 2.89(2.50–3.35) <0.001 3 GPA 774/918 67.5 0.026 NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
HLA-DR6 - 0.45(0.33–0.62) <0.001 4 GPA 301/6132 59.8 0.058 0.000 0.008 0.927 1.000 0.114 0.992 0.511 0.999
Rahmattulla, et al.
2016 [5]
IRF5
rs10954213 G
0.66
(0.59–0.74) <0.001 2 GPA 1021/6267 99.1 0.000 0.000 0.432 0.000 0.033 0.000 0.000 0.000 0.000
Rahmattulla, et al.
2016 [5]
PTPN22
rs2476601 A
1.43
(1.26–1.62) <0.001 4 GPA 1616/8678 0.0 0.411 0.003 0.774 0.006 0.867 0.000 0.024 0.002 0.649
Rahmattulla, et al.
2016 [5]
RING1/RXRB
rs213213 A
1.91
(1.73–2.10) <0.001 3 GPA 1132/7238 0.0 0.551 NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
RXRB
rs6531 C
1.70
(1.55–1.86) <0.001 3 GPA 1211/6955 96.5 0.000 NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
RXRB
rs9277935 T
0.37
(0.31–0.43) <0.001 3 GPA 1135/7233 0.0 0.798 NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
SERPINA 1 Z allele 2.40(1.73–3.33) <0.001 4 GPA 972/2636 0.0 0.763 0.000 0.002 0.906 1.000 0.062 0.985 0.282 0.997
Rahmattulla, et al.
2016 [5]
HLA-DRB4 - 2.06(1.57–2.69) <0.001 2 EGPA 150/691 0.4 0.316 0.000 0.010 0.754 1.000 0.011 0.918 0.089 0.990
Rahmattulla, et al.
2016 [5]
FPRP: false-positive report probability; BFDP: Bayesian false discovery probability; OR: odds ratio; 95% CI: 95% confidence interval; No.: number; NA: not applicable.
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Table 2. Meta-analysis results of observational studies; gene variants with statistical significance (p-value < 0.05), found to be noteworthy by FPRP or BFDP for each
serologic diagnosis (MPO-ANCA and PR3-ANCA).
Gene/
Variant
Minor
Allele/
Comparison
OR (95% CI)
p-Value for
Meta-Analysis
Publications
(n)
Diagnosis
(Serologic
Subtypes)
No. of
Cases/
Controls
I2 (%) I2 (P)
Egger’s
p-Value
Power
OR
1.2
Power
OR
1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001
Author, YearOR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
HLA-DPA1
rs9277341 C
0.27
(0.22–0.33) <0.001 1 PR3-ANCA 578/1820 - - NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
HLA-DPB1*0401 - 3.93(2.75–5.62) <0.001 2 PR3-ANCA 183/139 0.0 0.960 0.000 0.000 0.615 0.999 0.001 0.495 0.000 0.170
Rahmattulla, et al.
2016 [5]
HLA-DPB2
rs3130215 A
0.65
(0.55–0.77) <0.001 1 PR3-ANCA 326/5366 - - 0.002 0.385 0.235 0.997 0.002 0.618 0.062 0.985
Rahmattulla, et al.
2016 [5]
HLA-DRB1*15 - 2.82(2.00–3.96) <0.001 2 PR3-ANCA 131/582 84.0 0.002 0.000 0.000 0.842 1.000 0.016 0.942 0.040 0.977
Rahmattulla, et al.
2016 [5]
RING1/RXRB
rs213213 A
2.06
(1.75–2.41) <0.001 1 PR3-ANCA 326/5366 - - NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
RXRB
rs6531 C
2.19
(1.92–2.51) <0.001 1 PR3-ANCA 478/5251 - - NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
RXRB
rs9277935 T
0.24
(0.17–0.33) <0.001 1 PR3-ANCA 326/5350 - - NA NA NA NA NA NA 0.000 0.000
Rahmattulla, et al.
2016 [5]
SERPINA 1 Z allele 3.53(2.28–5.49) <0.001 5 PR3-ANCA 280/4788 21.3 0.279 0.000 0.000 0.963 1.000 0.229 0.997 0.512 0.999
Rahmattulla, et al.
2016 [5]
TLR9
rs352140 T
1.28
(1.12–1.45) 0.018 1 PR3-ANCA NR/NR 0.0 0.782 0.155 0.994 0.402 0.999 0.095 0.991 0.778 1.000
Rahmattulla, et al.
2016 [5]
TLR9
rs352162 T
1.30
(1.14–1.47) <0.001 1 PR3-ANCA NR/NR 0.0 0.503 0.101 0.989 0.221 0.996 0.028 0.967 0.532 0.999
Rahmattulla, et al.
2016 [5]
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Table 3. Results of meta analyses (combined analysis) with genome-wide association studies and replication cohort. Noteworthy genetic variants with satisfied FPRP
or BFDP values are presented. SNPs: single nucleotide polymorphism.
Gene/ Variant Comparison OR (95% CI) p-Value
Diagnosis
(Clinical/
Serologic
Subtypes)
Ethnicity
No. of
Cases/
Controls
Power
OR 1.2
Power
OR 1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001
Author, YearOR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
SNPs Statistically Significant (p < 5.00× 10−8)
HLA-DPA1
rs9277341 T vs. C 2.44 (2.21–2.69) 6.09 × 10
−71 AAV Caucasian 1986/4723 NA NA NA NA NA NA 0.000 0.000 Merkel, et al. 2017 [4]
HLA-DPB1
rs1042169 G vs. A 2.82 (2.54–3.13) 1.12 × 10
−84 AAV Caucasian 1986/4723 NA NA NA NA NA NA 0.000 0.000 Merkel, et al. 2017 [4]
HLA-DPB1
rs141530233 A del 2.99 (2.69–3.33) 1.13 × 10
−89 AAV Caucasian 1986/4723 NA NA NA NA NA NA 0.000 0.000 Merkel, et al. 2017 [4]
HLA-DQA1
rs35242582 A vs. G 1.60 (1.46–1.76) 6.34 × 10
−23 AAV Caucasian 1986/4723 NA NA NA NA NA NA 0.000 0.000 Merkel, et al. 2017 [4]
HLA-DQB1
rs1049072 A vs. G 1.40 (1.28–1.53) 6.46 × 10
−13 AAV Caucasian 1986/4723 0.000 0.936 0.000 0.000 0.000 0.000 0.000 0.000 Merkel, et al. 2017 [4]
PRTN3 rs62132293 G vs. C 1.29 (1.19–1.39) 8.60 × 10−11 AAV Caucasian 1986/4723 0.029 1.000 0.000 0.000 0.000 0.000 0.000 0.002 Merkel, et al. 2017 [4]
PTPN22 rs6679677 A vs. C 1.40 (1.25–1.57) 1.88 × 10−8 AAV Caucasian 1986/4723 0.004 0.881 0.002 0.172 0.000 0.001 0.001 0.447 Merkel, et al. 2017 [4]
SERPINA1
rs28929474 T vs. C 2.18 (1.75–2.71) 3.09 × 10
−12 AAV Caucasian 1986/4723 0.000 0.000 0.056 0.855 0.000 0.001 0.000 0.010 Merkel, et al. 2017 [4]
HLA-DPA1
rs9277341 C vs. T 0.33 (0.28–0.39) 2.18 × 10
−39 GPA Caucasian 750/1820 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPB1
rs9277554 T vs. C 0.24 (0.20–0.30) 1.92 × 10
−50 GPA Caucasian 750/1820 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
SEMA6A rs26595 C vs. T 0.74 (0.67–0.82) 2.09 × 10−8 GPA Caucasian 987/2731 0.012 0.977 0.001 0.071 0.000 0.001 0.001 0.423 Xie, et al. 2013 [6]
HLA-DQA2
rs3998159 C vs. A 2.72 (2.24–3.22) 5.24 × 10
−25 MPO-ANCA Caucasian 378/4723 NA NA NA NA NA NA 0.000 0.000 Merkel, et al. 2017 [4]
HLA-DQA2
rs7454108 C vs. T 2.73 (2.25–3.24) 5.03 × 10
−25 MPO-ANCA Caucasian 378/4723 NA NA NA NA NA NA 0.000 0.000 Merkel, et al. 2017 [4]
HLA-DQB1
rs1049072 A vs. G 2.37 (2.01–2,78) 2.13 × 10
−24 MPO-ANCA Caucasian 378/4723 NA NA NA NA NA NA 0.000 0.000 Merkel, et al. 2017 [4]
SNPs with Statistically Borderline Significance (5.00× 10−8 ≤ p < 0.05)
PTPN22(R620W)
rs2476601 A vs. G 1.36 (1.21–1.53) 1.86 × 10
−7 AAV Caucasian 1986/4723 0.019 0.948 0.016 0.625 0.000 0.032 0.020 0.953 Merkel, et al. 2017 [4]
CCDC86 rs595018 A vs. G 1.46 (1.27–1.69) 1.60 × 10−7 GPA Caucasian 1986/4723 0.004 0.641 0.084 0.902 0.001 0.058 0.033 0.971 Xie, et al. 2013 [6]
COBL rs1949829 T vs. C 1.78 (1.42–2.24) 4.19 × 10−7 GPA Caucasian 1986/4723 0.000 0.072 0.694 0.996 0.012 0.549 0.177 0.995 Xie, et al. 2013 [6]
DCTD rs4862110 C vs. T 1.44 (1.24–1.67) 2.14 × 10−6 GPA Caucasian 1986/4723 0.008 0.705 0.151 0.947 0.002 0.167 0.092 0.990 Xie, et al. 2013 [6]
DOK4 rs6023640 T vs. G 1.29 (1.14–1.45) 2.73 × 10−5 GPA Caucasian 987/2731 0.113 0.994 0.148 0.946 0.019 0.664 0.445 0.999 Xie, et al. 2013 [6]
FLJ34870
rs7585252 G vs. A 1.26 (1.13–1.40) 1.74 × 10
−5 GPA Caucasian 987/2731 0.182 0.999 0.086 0.904 0.017 0.632 0.408 0.999 Xie, et al. 2013 [6]
PAEP rs705669 G vs. A 0.77 (0.68–0.87) 2.52 × 10−5 GPA Caucasian 987/2731 0.102 0.990 0.210 0.964 0.027 0.733 0.520 0.999 Xie, et al. 2013 [6]
WSCD1 rs7503953 A vs. C 1.50 (1.29–1.76) 1.93 × 10−7 GPA Caucasian 1986/4723 0.003 0.500 0.176 0.955 0.001 0.117 0.058 0.984 Xie, et al. 2013 [6]
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Table 4. Re-analysis of the SNPs discovered in genome-wide association studies of patients with GPA. Noteworthy genetic variants with satisfied FPRP or BFDP
values are presented. Xie et al. only provided GPA SNPs with odds ratios (ORs) and 95% confidence intervals (CIs).
Gene/Variant Comparison OR (95% CI) p-Value
Diagnosis
(Clinical/
Serologic
Subtypes)
Ethnicity
No. of
Cases/
Controls
Power
OR 1.2
Power
OR 1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001
Author, YearOR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
SNPs with p-Value < 5.00× 10−8
HLA-DOA
rs3130604 G vs. A 1.67 (1.39–2.02) 4.39 × 10
−8 GPA Caucasian 459/1503 0.000 0.134 0.277 0.997 0.001 0.487 0.025 0.962 Xie, et al. 2013 [6]
HLA-DOA
rs763469 A vs. G 1.70 (1.41–2.04) 1.46 × 10
−8 GPA Caucasian 459/1503 0.000 0.089 0.114 0.992 0.000 0.116 0.003 0.764 Xie, et al. 2013 [6]
HLA-DPA1
rs2395309 G vs. A 0.27 (0.20–0.36) 2.15 × 10
−19 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPA1 rs3077 C vs. T 0.27 (0.20–0.36) 2.68 × 10−19 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPA1
rs2301226 T vs. C 0.48 (0.36–0.62) 4.85 × 10
−8 GPA Caucasian 459/1503 0.000 0.006 0.613 0.999 0.003 0.762 0.023 0.959 Xie, et al. 2013 [6]
HLA-DPA1
rs9277341 C vs. T 0.30 (0.25–0.38) 1.84 × 10
−30 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPB1
rs987870 C vs. T 0.26 (0.19–0.37) 6.09 × 10
−16 GPA Caucasian 459/1503 0.000 0.000 0.597 0.999 0.001 0.462 0.000 0.155 Xie, et al. 2013 [6]
HLA-DPB1
rs9277535 G vs. A 0.24 (0.19–0.32) 2.12 × 10
−28 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPB1
rs9277554 T vs. C 0.22 (0.17–0.28) 4.88 × 10
−38 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPB1
rs9277565 T vs. C 0.24 (0.18–0.32) 1.91 × 10
−24 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPB1
rs2281389 C vs. T 0.24 (0.18–0.34) 1.69 × 10
−20 GPA Caucasian 459/1503 0.000 0.000 0.458 0.999 0.000 0.187 0.000 0.013 Xie, et al. 2013 [6]
HLA-DPB1
rs3128917 G vs. T 0.22 (0.17–0.29) 4.92 × 10
−33 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPB1
rs3117222 A vs. G 0.22 (0.17–0.29) 3.05 × 10
−33 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPB2
rs2064478 A vs. G 0.22 (0.17–0.30) 4.29 × 10
−29 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPB2
rs3130215 A vs. G 2.42 (2.08–2.82) 2.37 × 10
−30 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPB2
rs3117230 C vs. T 0.22 (0.17–0.30) 4.29 × 10
−29 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPB2
rs1883414 T vs. C 0.53 (0.44–0.64) 1.13 × 10
−11 GPA Caucasian 459/1503 0.000 0.009 0.031 0.970 0.000 0.005 0.000 0.039 Xie, et al. 2013 [6]
HLA-DPB2
rs4713607 A vs. G 0.60 (0.52–0.70) 6.70 × 10
−11 GPA Caucasian 459/1503 0.000 0.090 0.006 0.849 0.000 0.001 0.000 0.027 Xie, et al. 2013 [6]
HLA-DPB2
rs3129274 G vs. A 1.56 (1.34–1.82) 1.35 × 10
−8 GPA Caucasian 459/1503 0.000 0.309 0.036 0.974 0.000 0.048 0.002 0.708 Xie, et al. 2013 [6]
HLA-DPB2
rs3117016 T vs. C 0.48 (0.41–0.57) 1.09 × 10
−17 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HLA-DPB2
rs3117008 T vs. C 0.60 (0.51-0.70) 4.90 × 10
−11 GPA Caucasian 459/1503 0.000 0.090 0.006 0.849 0.000 0.001 0.000 0.027 Xie, et al. 2013 [6]
HLA-DPB2
rs3117004 C vs. T 0.57 (0.48–0.68) 1.90 × 10
−10 GPA Caucasian 459/1503 0.000 0.041 0.034 0.972 0.000 0.010 0.000 0.161 Xie, et al. 2013 [6]
HLA-DPB2
rs6901221 C vs. A 0.42 (0.32–0.55) 6.08 × 10
−11 GPA Caucasian 459/1503 0.000 0.000 0.475 0.999 0.001 0.423 0.002 0.651 Xie, et al. 2013 [6]
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Table 4. Cont.
Gene/ Variant Comparison OR (95% CI) p-Value
Diagnosis
(Clinical/
Serologic
Subtypes)
Ethnicity
No. of
Cases/
Controls
Power
OR 1.2
Power
OR 1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001
Author, YearOR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
COL11A2 rs986521 C vs. T 1.85 (1.57–2.16) 2.91 × 10−14 GPA Caucasian 459/1503 0.000 0.004 0.000 0.246 0.000 0.000 0.000 0.000 Xie, et al. 2013 [6]
COL11A2
rs2855430 T vs. C 0.33 (0.24–0.45) 3.28 × 10
−13 GPA Caucasian 459/1503 0.000 0.000 0.505 0.999 0.001 0.357 0.000 0.237 Xie, et al. 2013 [6]
COL11A2
rs2855425 C vs. T 1.80 (1.54–2.11) 7.77 × 10
−14 GPA Caucasian 459/1503 0.000 0.012 0.001 0.594 0.000 0.000 0.000 0.000 Xie, et al. 2013 [6]
COL11A2
rs2855459 T vs. C 0.32 (0.23–0.44) 2.14 × 10
−13 GPA Caucasian 459/1503 0.000 0.000 0.548 0.999 0.001 0.427 0.000 0.287 Xie, et al. 2013 [6]
RXRB rs6531 C vs. T 1.80 (1.54–2.11) 8.48 × 10−14 GPA Caucasian 459/1503 0.000 0.012 0.001 0.594 0.000 0.000 0.000 0.000 Xie, et al. 2013 [6]
HSD17B8 rs439205 T vs. C 0.31 (0.24–0.39) 3.51 × 10−23 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
HSD17B8 rs421446 C vs. T 0.39 (0.31–0.48) 8.90 × 10−20 GPA Caucasian 459/1503 NA NA NA NA NA NA 0.000 0.000 Xie, et al. 2013 [6]
RING1 rs213213 A vs. G 1.83 (1.57–2.14) 6.98 × 10−15 GPA Caucasian 459/1503 0.000 0.006 0.001 0.375 0.000 0.000 0.000 0.000 Xie, et al. 2013 [6]
RING1 rs213212 G vs. T 1.85 (1.58–2.17) 7.63 × 10−15 GPA Caucasian 459/1503 0.000 0.005 0.001 0.439 0.000 0.000 0.000 0.000 Xie, et al. 2013 [6]
COBL rs1949829 T vs. C 2.19 (1.68–2.86) 3.58 × 10−9 GPA Caucasian 459/1503 0.000 0.003 0.632 0.999 0.003 0.759 0.017 0.946 Xie, et al. 2013 [6]
CCDC86 rs595018 A vs. G 1.61 (1.36–1.90) 2.74 × 10−8 GPA Caucasian 459/1503 0.000 0.201 0.064 0.986 0.000 0.080 0.003 0.764 Xie, et al. 2013 [6]
WSCD1 rs7503953 A vs. C 1.72 (1.44–2.06) 1.39 × 10−9 GPA Caucasian 459/1503 0.000 0.068 0.076 0.988 0.000 0.053 0.001 0.555 Xie, et al. 2013 [6]
SNPs Reported Non-Significant (5.00× 10−8 ≤ p < 1.00× 10−4)
TCEB3 rs2076346 C vs. T 1.46 (1.24–1.73) 8.62 × 10−6 GPA Caucasian 459/1503 0.012 0.623 0.512 0.999 0.019 0.952 0.433 0.999 Xie, et al. 2013 [6]
DAB1 rs264036 C vs. T 0.72 (0.62–0.85) 9.82 × 10−5 GPA Caucasian 459/1503 0.042 0.818 0.713 1.000 0.113 0.992 0.807 1.000 Xie, et al. 2013 [6]
DAB1 rs542873 T vs. C 1.37 (1.18–1.59) 4.70 × 10−5 GPA Caucasian 459/1503 0.041 0.884 0.457 0.999 0.037 0.975 0.601 0.999 Xie, et al. 2013 [6]
DAB1 rs197644 G vs. A 1.37 (1.18–1.59) 3.89 × 10−5 GPA Caucasian 459/1503 0.041 0.884 0.457 0.999 0.037 0.975 0.601 0.999 Xie, et al. 2013 [6]
LPHN2 rs11579502 C vs. T 1.56 (1.28–1.90) 9.43 × 10−6 GPA Caucasian 459/1503 0.005 0.348 0.684 1.000 0.027 0.966 0.458 0.999 Xie, et al. 2013 [6]
NCKAP5
rs1134119 C vs. T 1.79 (1.38–2.32) 8.96 × 10
−6 GPA Caucasian 459/1503 0.001 0.091 0.896 1.000 0.106 0.992 0.658 0.999 Xie, et al. 2013 [6]
NCKAP5
rs7585252 G vs. A 1.35 (1.16–1.57) 9.69 × 10
−5 GPA Caucasian 459/1503 0.063 0.914 0.607 0.999 0.096 0.991 0.785 1.000 Xie, et al. 2013 [6]
NEK10 rs1579900 T vs. G 1.51 (1.24–1.85) 3.97 × 10−5 GPA Caucasian 459/1503 0.013 0.474 0.840 1.000 0.128 0.993 0.800 1.000 Xie, et al. 2013 [6]
CTNNB1
rs9842536 T vs. C 1.46 (1.23–1.74) 1.63 × 10
−5 GPA Caucasian 459/1503 0.014 0.619 0.624 0.999 0.037 0.974 0.575 0.999 Xie, et al. 2013 [6]
C3orf58 rs1512779 C vs. A 0.72 (0.61–0.84) 2.86 × 10−5 GPA Caucasian 459/1503 0.032 0.836 0.484 0.999 0.034 0.972 0.579 0.999 Xie, et al. 2013 [6]
PLSCR4 rs7628805 A vs. C 1.41 (1.18–1.67) 9.72 × 10−5 GPA Caucasian 459/1503 0.031 0.763 0.691 1.000 0.083 0.989 0.754 1.000 Xie, et al. 2013 [6]
ST6GAL1
rs10513807 G vs. A 0.71 (0.61–0.83) 9.49 × 10
−6 GPA Caucasian 459/1503 0.022 0.785 0.436 0.999 0.021 0.956 0.471 0.999 Xie, et al. 2013 [6]
KIAA0746
rs4269167 T vs. C 0.73 (0.63–0.86) 7.72 × 10
−5 GPA Caucasian 459/1503 0.057 0.861 0.747 1.000 0.163 0.995 0.858 1.000 Xie, et al. 2013 [6]
DCTD rs4862110 C vs. T 1.63 (1.36–1.94) 5.00 × 10−8 GPA Caucasian 459/1503 0.000 0.175 0.118 0.993 0.000 0.178 0.007 0.878 Xie, et al. 2013 [6]
OSMR rs357291 C vs. A 0.72 (0.62–0.84) 2.81 × 10−5 GPA Caucasian 459/1503 0.032 0.836 0.484 0.999 0.034 0.972 0.579 0.999 Xie, et al. 2013 [6]
SEMA6A rs26595 C vs. T 0.74 (0.63–0.86) 9.58 × 10−5 GPA Caucasian 459/1503 0.061 0.913 0.586 0.999 0.086 0.989 0.766 1.000 Xie, et al. 2013 [6]
GRIA1 rs10515687 T vs. C 1.56 (1.25–1.94) 8.11 × 10−5 GPA Caucasian 459/1503 0.009 0.362 0.874 1.000 0.150 0.994 0.811 1.000 Xie, et al. 2013 [6]
WWC1 rs3853242 G vs. A 0.74 (0.63–0.86) 8.55 × 10−5 GPA Caucasian 459/1503 0.061 0.913 0.586 0.999 0.086 0.989 0.766 1.000 Xie, et al. 2013 [6]
ERGIC1 rs1564259 A vs. G 0.69 (0.58–0.83) 7.19 × 10−5 GPA Caucasian 459/1503 0.023 0.642 0.785 1.000 0.114 0.992 0.797 1.000 Xie, et al. 2013 [6]
ERGIC1 rs1006721 C vs. T 0.69 (0.58–0.83) 6.22 × 10−5 GPA Caucasian 459/1503 0.023 0.642 0.785 1.000 0.114 0.992 0.797 1.000 Xie, et al. 2013 [6]
OFCC1 rs9358619 A vs. G 1.45 (1.21–1.74) 4.90 × 10−5 GPA Caucasian 459/1503 0.021 0.642 0.756 1.000 0.092 0.990 0.762 1.000 Xie, et al. 2013 [6]
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Table 4. Cont.
Gene/ Variant Comparison OR (95% CI) p-Value
Diagnosis
(Clinical/
Serologic
Subtypes)
Ethnicity
No. of
Cases/
Controls
Power
OR 1.2
Power
OR 1.5
FPRP Values at Prior Probability
BFDP
0.001
BFDP
0.000001
Author, YearOR 1.2 OR 1.5
0.001 0.000001 0.001 0.000001
HLA-DMA
rs3135029 A vs. C 1.61 (1.28–2.02) 4.55 × 10
−5 GPA Caucasian 459/1503 0.006 0.270 0.875 1.000 0.125 0.993 0.764 1.000 Xie, et al. 2013 [6]
HLA-DOA
rs176248 T vs. C 0.70 (0.58–0.83) 8.16 × 10
−5 GPA Caucasian 459/1503 0.022 0.713 0.644 0.999 0.054 0.983 0.668 1.000 Xie, et al. 2013 [6]
HLA-DOA
rs206762 C vs. T 1.36 (1.17–1.58) 5.92 × 10
−5 GPA Caucasian 459/1503 0.051 0.900 0.534 0.999 0.061 0.985 0.703 1.000 Xie, et al. 2013 [6]
HLA-DOA
rs9296068 G vs. T 0.68 (0.58–0.81) 7.49 × 10
−6 GPA Caucasian 459/1503 0.011 0.588 0.578 0.999 0.026 0.964 0.491 0.999 Xie, et al. 2013 [6]
HLA-DPB2
rs1810472 G vs. A 0.65 (0.54–0.77) 1.06 × 10
−6 GPA Caucasian 459/1503 0.002 0.385 0.235 0.997 0.002 0.618 0.062 0.985 Xie, et al. 2013 [6]
HLA-DPB2
rs3117035 A vs. G 0.72 (0.61–0.84) 2.50 × 10
−5 GPA Caucasian 459/1503 0.032 0.836 0.484 0.999 0.034 0.972 0.579 0.999 Xie, et al. 2013 [6]
COL11A2
rs2235498 T vs. C 0.67 (0.55–0.81) 3.86 × 10
−5 GPA Caucasian 459/1503 0.012 0.521 0.744 1.000 0.063 0.985 0.678 1.000 Xie, et al. 2013 [6]
WDR46 rs3130257 T vs. C 1.63 (1.32–2.01) 5.61 × 10−6 GPA Caucasian 459/1503 0.002 0.218 0.700 1.000 0.022 0.957 0.365 0.998 Xie, et al. 2013 [6]
DAXX rs211474 T vs. C 0.71 (0.60–0.84) 6.37 × 10−5 GPA Caucasian 459/1503 0.031 0.769 0.679 1.000 0.078 0.988 0.744 1.000 Xie, et al. 2013 [6]
KIFC1 rs211452 C vs. T 0.65 (0.55–0.76) 1.98 × 10−7 GPA Caucasian 459/1503 0.001 0.375 0.067 0.986 0.000 0.150 0.008 0.895 Xie, et al. 2013 [6]
SYNGAP1
rs211456 A vs. C 0.72 (0.61–0.84) 3.57 × 10
−5 GPA Caucasian 459/1503 0.032 0.836 0.484 0.999 0.034 0.972 0.579 0.999 Xie, et al. 2013 [6]
SYNGAP1
rs2247385 G vs. A 0.69 (0.59–0.81) 5.14 × 10
−6 GPA Caucasian 459/1503 0.011 0.663 0.353 0.998 0.009 0.896 0.271 0.997 Xie, et al. 2013 [6]
FLJ43752 rs210120 G vs. A 0.72 (0.62–0.84) 2.58 × 10−5 GPA Caucasian 459/1503 0.032 0.836 0.484 0.999 0.034 0.972 0.579 0.999 Xie, et al. 2013 [6]
BCKDHB rs515347 G vs. A 1.70 (1.32–2.18) 3.13 × 10−5 GPA Caucasian 459/1503 0.003 0.162 0.905 1.000 0.151 0.994 0.769 1.000 Xie, et al. 2013 [6]
TCBA1 rs6924068 G vs. A 1.40 (1.20–1.63) 1.37 × 10−5 GPA Caucasian 459/1503 0.023 0.813 0.382 0.998 0.018 0.947 0.429 0.999 Xie, et al. 2013 [6]
MAGI2 rs3779312 A vs. G 1.50 (1.26–1.78) 5.26 × 10−6 GPA Caucasian 459/1503 0.005 0.500 0.392 0.998 0.007 0.873 0.214 0.996 Xie, et al. 2013 [6]
CUTL1 rs1734729 T vs. C 1.41 (1.20–1.67) 4.54 × 10−5 GPA Caucasian 459/1503 0.031 0.763 0.691 1.000 0.083 0.989 0.754 1.000 Xie, et al. 2013 [6]
DPP6 rs4726422 G vs. A 0.74 (0.63–0.86) 7.74 × 10−5 GPA Caucasian 459/1503 0.061 0.913 0.586 0.999 0.086 0.989 0.766 1.000 Xie, et al. 2013 [6]
LOC441376
rs3019885 G vs. T 1.44 (1.24–1.67) 1.90 × 10
−6 GPA Caucasian 459/1503 0.008 0.705 0.151 0.994 0.002 0.667 0.092 0.990 Xie, et al. 2013 [6]
SLC30A8
rs1793729 C vs. T 0.68 (0.57–0.80) 5.68 × 10
−6 GPA Caucasian 459/1503 0.007 0.594 0.317 0.998 0.006 0.847 0.194 0.996 Xie, et al. 2013 [6]
SLC30A8
rs1695715 T vs. C 0.69 (0.58–0.82) 1.57 × 10
−5 GPA Caucasian 459/1503 0.016 0.652 0.610 0.999 0.037 0.975 0.582 0.999 Xie, et al. 2013 [6]
KCNK9 rs2447406 T vs. C 1.58 (1.27–1.97) 3.25 × 10−5 GPA Caucasian 459/1503 0.007 0.322 0.869 1.000 0.130 0.993 0.781 1.000 Xie, et al. 2013 [6]
C9orf66 rs584922 T vs. C 0.70 (0.60–0.82) 1.30 × 10−5 GPA Caucasian 459/1503 0.015 0.727 0.392 0.998 0.013 0.932 0.365 0.998 Xie, et al. 2013 [6]
C9orf93 rs1341740 T vs. C 1.52 (1.23–1.87) 9.73 × 10−5 GPA Caucasian 459/1503 0.013 0.450 0.855 1.000 0.142 0.994 0.814 1.000 Xie, et al. 2013 [6]
LRRN6C
rs10491888 G vs. A 1.54 (1.25–1.91) 5.75 × 10
−5 GPA Caucasian 459/1503 0.012 0.405 0.880 1.000 0.173 0.995 0.837 1.000 Xie, et al. 2013 [6]
PAEP rs705669 G vs. A 0.69 (0.57–0.83) 8.53 × 10−5 GPA Caucasian 459/1503 0.023 0.642 0.785 1.000 0.114 0.992 0.797 1.000 Xie, et al. 2013 [6]
NEUROG3
rs731573 T vs. C 1.44 (1.20–1.72) 9.40 × 10
−5 GPA Caucasian 459/1503 0.022 0.674 0.722 1.000 0.079 0.988 0.738 1.000 Xie, et al. 2013 [6]
TMPO rs2216021 C vs. T 1.36 (1.17–1.57) 6.14 × 10−5 GPA Caucasian 459/1503 0.044 0.909 0.382 0.998 0.029 0.967 0.544 0.999 Xie, et al. 2013 [6]
TMPO rs2011247 C vs. T 0.73 (0.63–0.85) 4.84 × 10−5 GPA Caucasian 459/1503 0.044 0.879 0.534 0.999 0.054 0.983 0.680 1.000 Xie, et al. 2013 [6]
FGF9 rs2031421 T vs. G 1.44 (1.21–1.72) 4.01 × 10−5 GPA Caucasian 459/1503 0.022 0.674 0.722 1.000 0.079 0.988 0.738 1.000 Xie, et al. 2013 [6]
DOK5 rs6023640 T vs. G 1.40 (1.18–1.66) 8.98 × 10−5 GPA Caucasian 459/1503 0.038 0.786 0.740 1.000 0.121 0.993 0.815 1.000 Xie, et al. 2013 [6]
PDE9A rs2269127 A vs. G 1.65 (1.36–2.01) 4.06 × 10−7 GPA Caucasian 459/1503 0.001 0.172 0.457 0.999 0.004 0.793 0.094 0.990 Xie, et al. 2013 [6]
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between these two subtypes of ANCA-associated vasculitis. (B) PPI network of genes associated with
PR3-ANCA vasculitis. (C) PPI network of genes associated with MPO-ANCA vasculitis. Borderline
SNPs (5.0 × 10−8 < p < 0.05) from GWASs that have been noteworthy in our analysis were also
included. The yellow nodes represent the genes associated with the interferon-gamma-mediated
signaling pathway. The number of SNPs associated with PR3-ANCA and MPO-ANCA is 134 and 20,
respectively, which leads to a total of 21 and 8 unique genes. Note that some genes have multiple
SNPs associated with PR3-ANCA and MPO-ANCA. Among these genes, only 15 genes and 7 genes
are included in the PPI network by revealing known PPI interactions in Figure 2B,C.
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Figure 3. Protein–protein interaction network of associated genes in the etiopathogenesis of
ANCA-associated vasculitis. The size of the node indicates the number of noteworthy SNPs of each
gene. This network includes noteworthy SNPs and GWAS SNPs. The variants are listed in Table S7. The
yellow nodes represent the genes associated with the interferon-gamma-mediated signaling pathway.
To investigate i ease pathways, gen n ology (GO) enrichme t analysis was performed.
Several GO terms e riched in the SNPs s t were identified by GO enrichment analysis for each
subtype. Immune-related GO t rms, including “a igen proces ing an presentation of peptide
or polysaccharide ant en via MHC class II” (GO:0002504) with a p-value of 4.4 × 10−17,
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“interferon-gamma-mediated (IFN-γ) signaling pathway” (GO:0060333) with a p-value of 2.9 × 10−12,
and “T cell receptor signaling pathway” (GO:0050852) with a p-value of 5.5 × 10−10, were identified as
the most prominently enriched AAV-related gene sets (Figure 4 and Figure S3)
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Figure 4. Gene ontology enrichment analysis of ANCA-associated vasculitis. The analysis was
performed with the associated genetic variants. The cut-off p-value for this analysis was 0.01
(−log p-value = 2). Other subtype results are shown in the Figure S3.
3.3. Bullets
1. Several studies in ANCA-associated vasculitis have reported statistically significant genetic variants.
2. Integration and further analysis of the data from several studies using FPRP, BFDP, and GO
analysis identified novel biological pathways in ANCA-associated vasculitis, including a role of
the IFN-γ pathway.
3. Our results underline that there is a dichotomy between the respective target antigens, PR3
and MPO.
4. Discussion
In this study we investigated w ether the genetic variants previously found to be associated with
AAV are tr ly associated with AAV or are false-pos tives. Former studies h ve demonstrated that
the target antigens of AAV, MPO, and PR3 are better discriminators of the disease than the clinical
phenotypes, MPA and GPA [2]. Meta-analyses and GWASs have confirmed a genetic background of
AAV. Our analysis found no genetic overlap of MPO-ANCA and PR3-ANCA vasculitis. This further
underlines the need to distinguish both subtypes in clinical studies and may lead to a re-classification of
AAV based on the serotypes. Our analyses further highlight that AAV is not a multigenic disease with
the implication of several genetic variants contributi g to one’s individual risk to develop vasculitis.
This work used FPRP and BFDP estimation to re-analyze genetic associati ns from the retrieved
research papers. Discovered SNPs of each included study with p-values under 0.05 or either 5.0 × 10−8
were computed by both methods. Nearly half of the significant SNPs reported in meta-analyses of the
observational studies were not noteworthy, whereas those SNPs in GWASs and their meta-analyses
were noteworthy with FPRP and BFDP. However, when we applied the Bayesian procedures to SNPs
associated with borderline error probabilities (5.0 × 10−8 < p-value < 0.05) observed in a GWAS
including patients wit GPA, FPRP and BFDP computation yielded a noteworthiness of 85% of
these SNPs.
The exact mec anisms leading to AAV onset are unclear, but a gen tic predisposition and
self-intolerance to environmental exposures, such as infections, have been proposed [14]. A current
pathogenetic model proposes the initiation of an inflammatory cascade with the release of PR3
(pro-inflammatory cytokine) by an unknown insult, further selecting PR3-specific B lymphocytes
producing ANCA and PR3 specific T cells [14]. Subsequently, neutrophils are activated by ANCA
priming, leading to the destruction of endothelial cells by firmly attached neutrophils on endothelial
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cells [15,16]. Our GO enrichment analysis showed that the processing of antigens via MHC class II, the
IFN-γ-mediated pathway and the T cell receptor signaling pathway are the main biological processes
disturbed in AAV. GO enrichment analysis identified a crucial role of the IFN-γ mediated signaling
pathway and showed comparable involvement in both, MPO-ANCA and PR3-ANCA vasculitis. PPI
analysis revealed a role of the interferon regulatory factor 5 (IRF5) in the model including patients with
GPA and AAV. In systemic lupus erythematosus (SLE), IRF5 genetic variants are associated with an
increased risk to develop the disease, alongside elevation of IRF5 expression and IFN production [17].
IFN-γ has been studied in two biomarker studies involving a cohort with AAV and one cohort of
patients with GPA. Analysis of samples obtained from patients with AAV recruited to participate in
the RAVE trial indicated significant higher levels of IFN-γ during active disease compared to remission
(137 samples each) and to healthy controls (68 samples) [18]. Furthermore, the expression of chemokine
(C-X-C motif) ligand (CXCL10 or IFN-γ-induced protein 10) was tested in the same study. CXCL10
expression is dependent on IFN-γ and is implicated in several autoimmune disorders [19]. In patients
with AAV, CXCL10 levels did not differ among patients with active disease or in remission, while
CXCL10 levels were significantly lower in healthy controls. This argues for a sufficient reduction of
IFN-γ once remission is achieved in AAV, but in contrast, the levels of CXCL10 remain elevated. More
research is clearly needed to understand the regulation of the IFN-γ pathway in AAV.
IFN-γ increases MHC class II expression in antigen-presenting cells (B cells, macrophages, and
dendritic cells) that are engaged by microbial invasions [20,21]. Furthermore, IFN-γ negatively
regulates anti-inflammatory IL-10 production and induces pro-inflammatory IL-12 secretion [22].
IL-12 drives helper T(Th) cells to differentiate towards a Th1 phenotype and stimulates natural killer
(NK) cells to produce IFN-γ. IFN-γ secreted from NK cells induces monocyte differentiation towards
active macrophages in the local inflammatory site [23]. In addition, MPO stimulation leads to a
dose-dependent production of IFN-γ by monocytes [24]. MPO induces the formation of neutrophil
extracellular traps (NET), which is thought to be a crucial factor in the cascade of inflammation in
AAV [25]. The IFN-γ pathway may play a role in the development of local inflammation. Alongside the
immune system activation and NET formation as crucial mechanisms in the inflammatory processes,
our data confirm that genetic predisposition and the activation of antigen-presenting cells with the
selection of autoimmune T cells are important in the pathogenesis of AAV.
Our PPI network shows the mainframe structure of genetic interactions among HLA-associated
genes and COL11A2 in GPA, PR3-ANCA vasculitis, and AAV itself. COL11A2 gene codes for the
pro-α2 chain of collagen type XI. COL11A2 was demonstrated to be in linkage disequilibrium with
the HLA-DP gene in an AAV GWAS [3,26]. Except MHC coding genes, other genetic risk factors
associated with AAV were PTPN22, RXRB, CTLA-4, MICA, SERPINA1, PRTN3, CD226, TLR9, IRF5,
NOTCH4, AGER, and CFB, which is consistent with previous findings (Figure 3). PTPN22 encodes
protein tyrosine phosphatase in lymphoid tissues with an abnormal regulatory CD4 T-cell (Treg)
function and increased neutrophil function reported in PTPN22 variant (rs2476601) [27]. RXRB is
a gene encoding a family of retinoid X receptors, which form homodimers and heterodimers with
retinoic acid, thyroid hormone, and vitamin D receptors [28]. There was a functional difference in the
responsiveness to vitamin A and vitamin D in AAV patients, which could not be explained by RXRB
polymorphisms alone [29]. CTLA-4 is a gene encoding an inhibitory surface protein on activated T cells
that interacts with CD80 or CD86 and competes with CD28 (co-stimulatory molecule) [30]. Abatacept,
a selective modulator of the CD80/86-CD28 costimulatory signal was successfully used in patients
with non-severe GPA and is currently in a phase III trial (ABROGATE, NCT02108860), which suggests
that the CTLA-4 protein might be of importance in AAV pathogenesis [31]. SERPINA1 and PRTN3 are
also referred to as crucial genes in the pathogenesis of PR3-ANCA vasculitis [27]. PRTN3 is the gene
encoding PR3 that exists on the surface or in the cytoplasm of neutrophils, whereas SERPINA1 encodes
α-1 antitrypsin, the major inhibitory molecule of PR3. Previous findings suggest that PRTN3 genetic
variants determine the predominant location of PR3 in neutrophils, where it may affect the activity of
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neutrophils [27]. No noteworthy variants were observed in MPA, but genetic variants related to the
HLA-DR and HLA-DQ loci were found to be associated with MPO-ANCA vasculitis (Figure S2).
FPRP was criticized with respect to its heuristic derivation of the formula, especially with the use
of α and 1-β as the probabilities of observing values greater or less than the test quantities under a
null and alternative hypothesis [32]. Even though a labored statistical derivation exists, the concept of
“noteworthiness” originated from FPRP has influenced recent genetic studies [12]. Moreover, although
direct comparison between BFDP and FPRP is not possible, the behavior of both is similar in promoting
SNPs’ rankings [13]. BFDP produced more noteworthy findings than FPRP because the latter derives
smaller posterior null estimates due to the conditioning on tail areas unlike the reliance on point
estimates provided by BFDP [13,33].
Our study has some limitations. First, different GWASs included in this study share the
same cohorts. Therefore, slight overestimation of some sharing genes found in these studies may
exist. However, no effect will be present in the gene network analysis because weighting of a gene
corresponded to the number of significant SNPs in each gene. Second, we were not able to analyze
variants with incomplete data (those without 95% CIs). Thus, it was not possible to confirm that all
genome-wide significant SNPs satisfied the FPRP and BFDP thresholds. In fact, SNPs significant in
GWASs were included in GO enrichment analysis, suggesting that these SNPs would be noteworthy
due to previous results (Tables 4 and 4 and Tables S5 and S6). Furthermore, the low frequency of
patients with MPA in the included studies may have led to the finding of no noteworthy SNPs in our
re-analysis. Lastly, linkage disequilibrium and expression changes of SNPs were not considered in this
analysis, perhaps treating SNPs and its properties too simply. Further research comprising quantitative
expression of loci is needed.
Nevertheless, our study merged current results of genetic associations in AAV and its subtypes.
In addition, the investigation of false-positive results in genetic research proves that researchers
should pay careful attention when interpreting the positive results reported in previous papers.
All GWAS SNPs associated with a borderline p-value are worth further examination with various
statistical methods, as we found many of them to be noteworthy with the used Bayesian methods.
Moreover, we highlight the importance of the IFN-γ pathway in the pathogenesis of AAV through
GO enrichment analysis using GWAS and meta-analysis gene sets. This suggests that further research
into the IFN-γ pathway in AAV may lead to the development of novel therapeutic approaches for this
complex disease.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/2/266/s1.
Figure S1: The Venn diagram for all subtypes and AAV with the noteworthy SNPs from our FPRP and BFDP
analyses. Figure S2: Protein–protein interaction network of GPA (A), MPO-ANCA vasculitis (B), PR3-ANCA
vasculitis (C), and ANCA-associated vasculitis (D). Genes are weighted according to the number of the SNPs
of each gene. The gene set was composed of GWAS discovered SNP genes and noteworthy SNP genes in the
meta-analyses of observational studies and GWAS meta-analyses. Borderline SNPs (5.0 × 10−8 < p < 0.05) from
GWASs that are noteworthy were also included in this analysis. Figure S3. Gene ontology enrichment analysis of
GPA (A), MPO-ANCA vasculitis (B), PR3-ANCA vasculitis (C), and ANCA-associated vasculitis (D). The gene set
was composed of GWAS discovered SNP genes and noteworthy SNP genes in the meta-analyses of observational
studies and GWAS meta-analyses. Borderline SNPs (5.0 × 10−8 < p < 0.05) from GWASs that are noteworthy were
also included in this analysis. Table S1: Preferred Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) checklist. Table S2. List of publications included in this re-analysis. Table S3. Meta-analysis results
of observational studies, gene variants with statistical significance (p-value < 0.05) for each clinical diagnosis
(AAV, GPA, and MPA). Summary of genetic variants with FPRP and BFDP values, and noteworthy genetic
variants are shown in bold. Table S4. Meta-analysis results of observational studies; gene variants with statistical
significance (p-value < 0.05) for each serologic diagnosis (MPO-ANCA, PR3-ANCA). Summary of genetic variants
with FPRP and BFDP values, and noteworthy genetic variants are shown in bold. Table S5. Results of meta
analyses (combined analysis) with genome-wide association studies and replication cohort. Noteworthy genetic
variants with satisfied FPRP and BFDP values are shown in bold. Table S6. Re-analysis of the SNPs discovered in
genome-wide association studies of patients with GPA. Xie et al. only provided GPA SNPs with ORs and 95% CIs.
Table S7: These gene sets were computed in gene ontology enrichment analysis and protein–protein interaction
network analysis. This gene set include noteworthy variants from meta-analyses and statistically significant
GWAS SNPs. Equation S1: Calculation of false positive report probability (FPRP) and Bayesian false discovery
probability (BFDP).
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